<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668497</url>
  </required_header>
  <id_info>
    <org_study_id>107433</org_study_id>
    <nct_id>NCT02668497</nct_id>
  </id_info>
  <brief_title>Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to study the efficacy of botulinum toxin type A (BoNT-A) injected
      via kinematic parameters in the treatment of unilateral/bilateral upper extremity tremor in
      Parkinson's disease (PD) tremor. Kinematic assessment tools already developed in past
      clinical studies will be used in determining injection parameters. The objective is to study
      the composition of PD tremor using kinematic tools which may contribute to the knowledge of
      tremor complexity and contribute information that would benefit the development of injection
      parameters to improve efficacy and optimization of BoNT-A in tremor management. By injecting
      all bothersome tremulous upper limbs in Parkinson's disease patients, the investigators
      believe a greater improvement in Quality of Life on more daily tasks can be achieved compared
      to the investigator's earlier study in unilateral injections (REB#101749), which already
      showed significant improvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinematic tremor severity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from pre to post-BoNT-A treatments in maximum angular tremor amplitude at the wrist in each treated arm. Angular tremor amplitude is one parameter reflecting the vectoral intensity of tremor segmented at each arm joint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical tremor severity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Improvement in upper limb tremor severity as determined by an increase &gt;8 points on a standardized clinical assessment tool (Fahn-Tolosa-Marin Tremor Assessment Scale) pre and post BoNT-A injection using kinematic-determined injection parameters in both ET upper limbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accelerometric kinematic tremor severity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from pre and post-BoNT-A treatments in maximum log-transformed accelerometric tremor amplitude at wrist level (injected limb). Log-transformed accelerometric tremor amplitude is one parameter reflecting the non-vectoral intensity of tremor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>48 weeks</time_frame>
    <description>Quality of life for essential tremor questionnaire is used to measure the patient's impression of change due to treatment and its change on their quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>BoNT-A in de-novo Parkinson's disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BoNT-A in L-dopa Parkinson's disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <arm_group_label>BoNT-A in de-novo Parkinson's disease patients</arm_group_label>
    <arm_group_label>BoNT-A in L-dopa Parkinson's disease patients</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PD individuals diagnosed by UK Brain Bank Criteria with stage H&amp;Y2-3 disease

          -  PD participants who are naïve to PD medications will be grouped into the &quot;De novo&quot; PD
             group

          -  PD participants stable on a low dose of Levodopa or on their PD medications for at
             least 3 months prior to their study enrolment will be grouped into the &quot;L-dopa&quot; PD
             group

          -  Participants who are botulinum toxin naïve for tremor management

          -  Patients will be screened for pregnancy by the physician

          -  Individuals with PD will be eligible for the study only if tremor is their primary and
             most bothersome symptom as determined by clinical exam and patient report denoting
             tremor-dominant phenotype

          -  Participants must be able to provide informed consent and to complete all study
             assessment scales and tasks.

        Exclusion Criteria:

          -  History of stroke

          -  History of ALS or Myasthenia Gravis

          -  History of COPD or emphysema

          -  Underlying arm muscle weakness or any related compartmental muscle syndrome

          -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
             agonists (e.g. salbutamol).

          -  Persons prescribed zonisamide

          -  History of allergic or side effect reaction to botulinum toxin

          -  Contraindications per the BoNT-A drug monograph

          -  Women reporting that they are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandar Jog, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32758</phone_ext>
      <email>mandar.jog@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Milanov I. A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor. Parkinsonism Relat Disord. 2001 Sep;8(1):67-73.</citation>
    <PMID>11472883</PMID>
  </reference>
  <reference>
    <citation>Kraus PH, Lemke MR, Reichmann H. Kinetic tremor in Parkinson's disease--an underrated symptom. J Neural Transm (Vienna). 2006 Jul;113(7):845-53. Epub 2006 Jan 30.</citation>
    <PMID>16804646</PMID>
  </reference>
  <reference>
    <citation>Jiménez MC, Vingerhoets FJ. Tremor revisited: treatment of PD tremor. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S93-5. doi: 10.1016/S1353-8020(11)70030-X. Review.</citation>
    <PMID>22166467</PMID>
  </reference>
  <reference>
    <citation>Imbach LL, Sommerauer M, Leuenberger K, Schreglmann SR, Maier O, Uhl M, Gassert R, Baumann CR. Dopamine-responsive pattern in tremor patients. Parkinsonism Relat Disord. 2014 Nov;20(11):1283-6. doi: 10.1016/j.parkreldis.2014.09.007. Epub 2014 Sep 16.</citation>
    <PMID>25260965</PMID>
  </reference>
  <reference>
    <citation>Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan 8;58(1):11-7.</citation>
    <PMID>11781398</PMID>
  </reference>
  <reference>
    <citation>Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8. doi: 10.1016/S1353-8020(09)70004-5. Review.</citation>
    <PMID>19131039</PMID>
  </reference>
  <reference>
    <citation>Stathis P, Konitsiotis S, Antonini A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev Neurother. 2015 Feb;15(2):207-13. doi: 10.1586/14737175.2015.1001747. Epub 2015 Jan 12. Review.</citation>
    <PMID>25578445</PMID>
  </reference>
  <reference>
    <citation>Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003735. Review.</citation>
    <PMID>12804486</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Mandar Jog</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Movement disorders</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Tremor</keyword>
  <keyword>Kinematics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

